<DOC>
	<DOCNO>NCT01518153</DOCNO>
	<brief_summary>The goal clinical research study learn dose kind immune cell call T-lymphocytes ( T-cells ) give donor infusion 8-9 week stem cell transplant best result . The safety treatment also study . This tested patient leukemia , MDS , lymphoma , Hodgkin disease , multiple myeloma . These result measure help control disease without severe graft-versus-host disease ( GvHD ) . GvHD transplant donor tissue attack tissue recipient 's body . Fludarabine , melphalan , alemtuzumab commonly give stem cell transplant : - Fludarabine design interfere DNA ( genetic material ) cancer cell , may cause cancer cell die . - Melphalan design bind DNA cell , may cause cancer cell die . - Alemtuzumab design weaken immune system reduce risk rejection transplant graft-vs-host disease ( GvHD ) . The donor infusion T-cells design help restore immune system transplant , cause immune reaction cancer , reduce risk cancer come back .</brief_summary>
	<brief_title>Planned Donor Lymphocyte Infusion ( DLI ) After Allogeneic Stem Cell Transplantation ( SCT )</brief_title>
	<detailed_description>Study Groups : If agree take part study , randomly assign ( flip coin ) 1 2 study group involve dose T-cells donor lymphocyte infusion . - Group 1 receive low dose donor T-cells . - Group 2 receive high dose donor T-cells Group 1 . Both study doctor know group . Both group stem cell transplant . The stem cell give vein . The cell travel bone marrow design make healthy , new blood cell several week . Study Drug Administration : Patients receive fludarabine , melphalan alemtuzumab kill malignant cell suppress immunity prevent rejection stem cell transplant . The day receive stem cell call Day 0 . The day receive stem cell call minus day . The day receive stem cell call plus day . On Day -7 , admit hospital give fluid vein hydrate . On Days -6 -3 , receive fludarabine vein 1 hour day . On Day -2 , receive melphalan vein 30 minute . On Day -1 , receive alemtuzumab vein 2 hour . On Day 0 , receive stem cell transplant cell infusion vein . After transplant , receive tacrolimus methotrexate . At first , receive tacrolimus continuous ( nonstop ) infusion able take mouth . You take tacrolimus mouth 2 time day 5 week doctor tell taper ( gradually stop take ) . On Days 1 , 3 , 6 transplant , receive methotrexate vein 30 minute . You receive filgrastim injection skin 1 time day , start 1 week transplant , blood cell level return normal . Filgrastim design help growth white blood cell . Between Day +56 +64 , stable medical condition develop GvHD , receive donor lymphocyte infusion contain T-cells vein 10-30 minute . You receive Benadryl ( diphenhydramine ) vein 15 minute infusion low risk allergic reaction . Study Visits : Before T-cell infusion : - You physical exam , include measurement vital sign ( blood pressure , heart rate , temperature , breathe rate ) . - You ask feel side effect may . - Blood ( 2 teaspoon ) drawn see well transplant `` take '' . - You bone marrow aspiration biopsy check status disease , doctor think need . To collect bone marrow aspiration/biopsy , area hip site numb anesthetic , small amount bone marrow bone withdrawn large needle . After T-cell infusion , physical exam every week least 6 week . About 3 , 6 , 12 month transplant : - You physical exam , include measurement vital sign . - You ask feel side effect may . - Blood ( 4 tablespoon ) draw routine test check level infuse T-cells , immune function test , check status disease . - You bone marrow aspiration , blood test CT scan medically necessary check status disease , doctor think need . During study , blood draw ( 2 teaspoon ) urine collect routine test , check blood count , kidney liver function , and/or check infection often doctor think need time . Length Treatment : You study 12-month follow-up visit . You take study early graft failure ( donor cell `` take '' ) cancer come back need another treatment . This investigational study . Melphalan , fludarabine , alemtuzumab FDA approve commercially available treatment blood cancer . Donor T-cell infusion commonly use treat blood cancer come back stem cell transplant . The investigational part study find best dose T-cells give goal help prevent cancer come back . Up 56 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Age &gt; /= 18 year &lt; /= 65 year one following : . Acute leukemia past first remission , first subsequent relapse , second great remission . Patients first remission intermediate high cytogenetic risk factor flt3 mutation . Patients primary induction failure relapse eligible &lt; 10 % bone marrow blast , circulate blast . b. Myelodysplastic syndrome intermediate high risk IPSS score , treatment related MDS . c. CML resistant tyrosine kinase inhibitor treatment first subsequent chronic phase , accelerated phase . d. CLL , Lymphoma Hodgkin 's disease fail achieve remission recur follow initial chemotherapy . Patients must least PR salvage therapy , low bulk untreated relapse ( &lt; 2 cm large mass ) . e. Multiple myeloma relapse progress achieve partial response salvage chemotherapy . 2 . Patients must one follow donor type identify willing donate : . Related donor , HLAmatched HLAA , B , C DR match , b . Matched Unrelated Donor ( MUD ) , HLAmatched HLA A , B , C DRB1 use allele level typing . 3 . Performance score least 80 % Karnofsky performance score 0 2 ( ECOG ) . 4 . Estimated creatinine clearance &gt; 40 ml/min ( base serum creatinine ) 5 . Bilirubin &lt; 1.5 mg/dl except Gilbert 's disease . 6 . ALT &lt; 300 IU/ml d. 7 . Left ventricular ejection fraction equal great 40 % . 8 . Pulmonary function test ( PFT ) demonstrate diffusion capacity ( correct hemoglobin ) least 50 % predict . 9 . Patient patient 's legal representative able sign inform consent . 1 . Patients prior autologous transplant prior allogeneic transplant eligible . 2 . Uncontrolled active infection . 3 . Positive Beta HCG test woman child bear potential , define postmenopausal 12 month previous surgical sterilization . 4 . Women child bear potential willing use effective contraceptive measure study . 5 . Subject know sensitivity product administer study . 6 . Patients HIV seropositive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Blood Marrow Transplantation</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Myeloproliferative Diseases</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Hodgkin disease</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>NeupogenTM</keyword>
	<keyword>Donor Lymphocyte Infusion</keyword>
	<keyword>DLI</keyword>
	<keyword>Allogeneic Stem Cell Transplantation</keyword>
	<keyword>Graft-vs-host disease</keyword>
	<keyword>GvHD</keyword>
	<keyword>T-lymphocytes</keyword>
	<keyword>T-cells</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>CAMPATH-1H</keyword>
	<keyword>Campath</keyword>
</DOC>